Collectively, these findings indicated that HDAC6 inhibition delays tumor growth in vivo and suggest that anti-tumor activity was mediated, at least in part, through its inhibition of EWSR1-FLI1 oncogene expression. Here, HDAC6 is linked to neoplasm.